Grant4

Bolt Biotherapeutics, Inc.

Total Value

Filing Date

Oct 27, 2026

2 transactions

Trade Summary

On Oct 23, 2026, GUJRATHI SHEILA, Insider, reported $0 of Bolt Biotherapeutics, Inc. (BOLT) across 2 transactions. The filing covers Common Stock and reflects balanced net activity of $0. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Insider Information

Name: GUJRATHI SHEILA
Role: Insider
Location: REDWOOD CITY, CA

Filing Details

Filing Date: Oct 27, 2026
Transaction Date: Oct 23, 2026
Accession Number: 0001193125-26-434468
Form Type: 4

Non-Derivative Transactions

Date	Security	Shares	Price	Type	Value
Oct 23, 2026	Common Stock	72,766	—	Grant/Award	—
Oct 23, 2026	Common Stock	13,055	—	Grant/Award	—

Derivative Transactions

Date	Security	Shares	Exercise Price	Type	Value
Oct 23, 2026	BOLT derivative	2,763.833	—	Other	—
Oct 23, 2026	BOLT derivative	495.874	—	Other	—

Want live alerts when GUJRATHI SHEILA trades again?

Download Insider Trades to track BOLT, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)Received in exchange for shares of common stock of Prana Therapies, Inc. ("Prana") pursuant to the Agreement and Plan of Merger dated October 23, 2026 (the "Merger Agreement") by and among the Issuer, Prana, Prince Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("Merger Sub I"), Prince Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer ("Merger Sub II"). Each outstanding share of Prana common stock was converted into the right to receive 1.6413 shares of the Issuer's common stock or common-stock equivalents, consisting of Issuer's common stock and Series D Convertible Preferred Stock ("Series D Preferred") convertible at a rate of 1,000 shares of Issuer's common stock per share of Series D Preferred. No cash purchase price was paid for the Series D Preferred received as merger consideration.
(F2)Upon closing of the merger on October 23, 2026, Prana shares held directly by the Reporting Person converted into 72,766 shares of Issuer's common stock and 2,763.833 shares of Series D Preferred. Prana shares held by SilverArc Private Fund I, L.P. converted into 13,055 shares of Issuer's common stock and 495.874 shares of Series D Preferred. The 495.874 shares of Series D Preferred constitute merger consideration
(F3)The Reporting Person is Co-Portfolio Manager and has membership interest in SilverArc Private Capital I, LLC (Ultimate General Partner), SilverArc Private Capital I, LP (General Partner), and SilverArc Private Capital Management I, LP (Management Company) for SilverArc Private Fund I, L.P. The Reporting Person may not be deemed to have voting or investment power over the shares held of record by SilverArc Private Fund I, LP. The Reporting Person disclaims beneficial ownership of the Non-Derivative and Derivative securities held of record by SilverArc Private Fund I, L.P., except to the extent of any pecuniary interest therein.
(F4)Each share of Series D Preferred is convertible into 1,000 shares of the Issuer's common stock, subject to the conditions set forth in the Certificate of Designation, including receipt of the requisite stockholder approval. The Series D Preferred has no expiration date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GUJRATHI SHEILA

(Last)

(First)

(Middle)

900 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY

94063

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Bolt Biotherapeutics, Inc. [ BOLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Strategy Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/23/2026		A⁽¹⁾⁽²⁾		72,766	A	$0⁽¹⁾⁽²⁾	72,766	D
Common Stock	10/23/2026		A⁽¹⁾⁽²⁾		13,055	A	$0⁽¹⁾⁽²⁾	13,055	I	By SilverArc Private Fund I, L.P.⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Series D Preferred Stock	⁽⁴⁾	10/23/2026	⁽⁴⁾	J		2,763.833		⁽⁴⁾	⁽⁴⁾	Common Stock	2,763,833	⁽¹⁾⁽²⁾	2,763.833	D
Series D Preferred Stock	⁽⁴⁾	10/23/2026		J⁽⁴⁾		495.874		⁽⁴⁾	⁽⁴⁾	Common Stock	495,874	⁽¹⁾⁽²⁾	495.874	I	By SilverArc Private Fund I, L.P.⁽³⁾

Explanation of Responses:

1. Received in exchange for shares of common stock of Prana Therapies, Inc. ("Prana") pursuant to the Agreement and Plan of Merger dated October 23, 2026 (the "Merger Agreement") by and among the Issuer, Prana, Prince Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("Merger Sub I"), Prince Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer ("Merger Sub II"). Each outstanding share of Prana common stock was converted into the right to receive 1.6413 shares of the Issuer's common stock or common-stock equivalents, consisting of Issuer's common stock and Series D Convertible Preferred Stock ("Series D Preferred") convertible at a rate of 1,000 shares of Issuer's common stock per share of Series D Preferred. No cash purchase price was paid for the Series D Preferred received as merger consideration.

2. Upon closing of the merger on October 23, 2026, Prana shares held directly by the Reporting Person converted into 72,766 shares of Issuer's common stock and 2,763.833 shares of Series D Preferred. Prana shares held by SilverArc Private Fund I, L.P. converted into 13,055 shares of Issuer's common stock and 495.874 shares of Series D Preferred. The 495.874 shares of Series D Preferred constitute merger consideration

3. The Reporting Person is Co-Portfolio Manager and has membership interest in SilverArc Private Capital I, LLC (Ultimate General Partner), SilverArc Private Capital I, LP (General Partner), and SilverArc Private Capital Management I, LP (Management Company) for SilverArc Private Fund I, L.P. The Reporting Person may not be deemed to have voting or investment power over the shares held of record by SilverArc Private Fund I, LP. The Reporting Person disclaims beneficial ownership of the Non-Derivative and Derivative securities held of record by SilverArc Private Fund I, L.P., except to the extent of any pecuniary interest therein.

4. Each share of Series D Preferred is convertible into 1,000 shares of the Issuer's common stock, subject to the conditions set forth in the Certificate of Designation, including receipt of the requisite stockholder approval. The Series D Preferred has no expiration date.

	/s/ Sheila Gujrathi	10/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 4 as rendered by the SEC from accession 0001193125-26-434468.

Bolt Biotherapeutics, Inc.

Trade Summary

Company Information

Insider Information

Filing Details

Non-Derivative Transactions

Derivative Transactions

Want live alerts when GUJRATHI SHEILA trades again?

Footnotes

SEC Form 4

SEC Filing

SEC Form 4